Home
  >  
Section 9
  >  
Chapter 8,406

Cutaneous mast cell degranulation in rats receiving injections of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) and/or its vehicle: possible clinical implications

Bendele, A.; Colloton, M.; Vrkljan, M.; Morris, J.; Sabados, K.

Journal of Laboratory and Clinical Medicine 125(4): 493-500

1995

ISSN/ISBN: 0022-2143
PMID: 7706905
Accession: 008405637
Download citation:  
Text
  |  
BibTeX
  |  
RIS
Human recombinant interleukin-1 receptor antagonist (rhIL-1ra), a 17.2 kd protein, is currently in clinical trials for the treatment of rheumatoid arthritis (RA). Skin reactions in some patients with RA prompted investigation of a possible pathogenesis involving nonimmunologically mediated most cell degranulation.

PDF emailed within 1 workday: $29.90




Related References

Morris, O.; McMahon, A.; Boutin, H.; Grigg, J.; Prenant, C. 2016: Automation of [(18) F]fluoroacetaldehyde synthesis: application to a recombinant human interleukin-1 receptor antagonist (rhIL-1RA) Journal of Labelled Compounds and Radiopharmaceuticals 59(7): 277-283
Di, Chung-Hui 1993: Expression of human recombinant interleukin-1 receptor antagonist (rhIL-1ra) in E. coli with high efficiency Chinese Journal of Microbiology and Immunology 13(5): 285-287
Clutterbuck, E.J.; Sanderson, C.J. 1990: Regulation of human eosinophil precursor production by cytokines: a comparison of recombinant human interleukin-1 (rhIL-1), rhIL-3, rhIL-5, rhIL-6, and rh granulocyte-macrophage colony-stimulating factor Blood 75(9): 1774-1779
Shen, J.; Gao, J.; Zhang, J.; Xiang, D.; Wang, X.; Qian, L.; Shen, J.; Yang, L.; Zhu, S.; Wu, M.; Yu, Y.; Han, W.; Wang, X. 2012: Recombinant human interleukin-1 receptor antagonist (rhIL-1Ra) attenuates caerulein-induced chronic pancreatitis in mice Biomedicine and PharmacoTherapy 66(2): 83-88
Fujii, Y.; Imamura, M.; Hashino, S.; Kobayashi, H.; Kobayashi, M.; Kasai, M.; Sakurada, K.; Miyazaki, T. 1992: Therapy with cytokines and biological response modifiers brms prior to syngeneic bone marrow transplantation in mice effect of recombinant human interleukin 1 beta rhil 1 beta interleukin 2 rhil 2 interleukin 6 rhil 6 recombinant murine tumor necrosis factor alpha rmtnf alpha and chinese herbal medicine ninjin youei to nyt on immunohematologic reconstitution Biomedicine and Pharmacotherapy 46(5-7): 315
Lohman, R-Jan.; Cotterell, A.J.; Barry, G.D.; Liu, L.; Suen, J.Y.; Vesey, D.A.; Fairlie, D.P. 2012: An antagonist of human protease activated receptor-2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagen-induced arthritis in rats Faseb Journal: Official Publication of the Federation of American Societies for Experimental Biology 26(7): 2877-2887
Modi M.; Nadeau R.; Ni Wu G.; Della Valle C.; Olejnik N.; Hayes T.; Liberato D. 1991: The pharmacokinetics of recombinant human interleukin 1 alpha rhil 1 alpha in rats that received single ascending intravenous doses of rhil 1 alpha and the resultant dose dependent concentrations of endogenous serum interleukin 6 il 6 FASEB Journal 5(6): A1567
Aoki, I.; Homori, M.; Nakahara, K.; Higashi, K.; Ishikawa, K. 1995: Effects of rhIL-1 alpha, rhIL-1 beta, and rhIL-1 receptor antagonist on erythroid progenitors (CFU-E and BFU-E) in human bone marrow Experimental Hematology 23(3): 217-225
Ferrari, S.; Danova, M.; Porta, C.; Brugnatelli, S.; Pugliese, P.; Bertolini, A.; Riccardi, A. 2002: Recombinant human interleukin-11 (Neumega, rhIL-11) reduces thrombocytopenia in breast cancer patients receiving tandem autologous circulating progenitor cell transportation Annals of Hematology 81(6): 354-356
Foureau, D.M.; Vrikkis, R.M.; Jones, C.P.; Weaver, K.D.; Macfarlane, D.R.; Salo, J.C.; McKillop, I.H.; Elliott, G.D. 2012: In vitro assessment of choline dihydrogen phosphate (CDHP) as a vehicle for recombinant human interleukin-2 (rhIL-2) Cellular and Molecular Bioengineering 5(4): 390-401
Rodgers, S.; Rees, R.C.; Hancock, B.W. 1994: Changes in the phenotypic characteristics of eosinophils from patients receiving recombinant human interleukin-2 (rhIL-2) therapy British Journal of Haematology 86(4): 746-753
Dvorak, A.M.; Costa, J.J.; Monahan-Earley, R.A.; Fox, P.; Galli, S.J. 1998: Ultrastructural analysis of human skin biopsy specimens from patients receiving recombinant human stem cell factor: subcutaneous injection of rhSCF induces dermal mast cell degranulation and granulocyte recruitment at the injection site Journal of Allergy and Clinical Immunology 101(6 Part 1): 793-806
Caron, J.P.; Fernandes, J.C.; Martel Pelletier, J.; Geng, C.S.; Mineau, F.; Tardif, G.; Pelletier, J.P. 1995: Protective effects of intraarticular injections of human recombinant interleukin-1 receptor antagonist in experimental canine osteoarthritis Arthritis and Rheumatism 38(9 Suppl): S160
Klimka, A.; Barth, S.; Drillich, S.; Wels, W.; van Snick, J.; Renauld, J.C.; Tesch, H.; Bohlen, H.; Diehl, V.; Engert, A. 1996: A deletion mutant of Pseudomonas exotoxin-A fused to recombinant human interleukin-9 (rhIL-9-ETA') shows specific cytotoxicity against IL-9-receptor-expressing cell lines Cytokines and Molecular Therapy 2(3): 139-146
Lee, E.; Min, H.-K.; Oskeritzian, C.A.; Kambe, N.; Schwartz, L.B.; Wook Chang, H. 2003: Recombinant human (rh) stem cell factor and rhIL-4 stimulate differentiation and proliferation of CD3+ cells from umbilical cord blood and CD3+ cells enhance FcepsilonR1 expression on fetal liver-derived mast cells in the presence of rhIL-4 Cellular Immunology 226(1): 30-36